Skip to main content

Table 4 Time-to-onset analysis of bisphosphonates stratified by formulations and dosages

From: Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events

Dosage form Drug name Case (number for analysis) Median of time-to-onset (day) Lower quartile of time-to-onset (day) Upper quartile of time-to-onset (day) Scale parameter: α Shape parameter: β
α (95 % CI) β (95 % CI)
Intravenous Pamidronate (30 − 45 mg) 44 (35) 844 658 1,199 775.6 (641.8 − 928.9) 1.98 (1.49 − 2.53)
  Pamidronate (90 mg) 66 (48) 783 532 1,041 889.5 (706.1 − 1112.6) 1.35 (1.09 − 1.63)
  Zoredronate (4 mg) 494 (355) 488 290 811 634.1 (587.7 − 683.4) 1.46 (1.34 − 1.59)
Oral Arendronate (5 mg) 155 (72) 1,263 757 1,951 1450.5 (1258.1 − 1664.5) 1.77 (1.46 − 2.12)
  Arendronate (35 mg) 202 (102) 680 309 1,106 804.9 (663.0 − 972.3) 1.08 (0.91 − 1.25)
  Risedronate (2.5 mg) 73 (39) 1,081 495 1,706 1288.6 (1008.4 − 1634.3) 1.41 (1.06 − 1.82)
  Risedronate (17.5 mg) 35 (14) 112 33 407 295.0 (129.5 − 636.9) 0.82 (0.96 − 1.23)